Document Detail

How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore.
MedLine Citation:
PMID:  19192158     Owner:  NLM     Status:  MEDLINE    
Hepatitis B virus (HBV) infection is the most common cause of chronic viral liver disease in Singapore. Nevertheless, very little data exist on the financial burden of HBV infection to the society as a whole. The aim of this study was therefore to assess the direct and indirect cost of HBV infection in a cost-of-illness analysis. The combined data from the direct and indirect cost with the estimated prevalence for different disease stages of HBV infection would represent the annual financial burden of HBV infection to the Singaporean society as a whole. The estimated total annual cost of chronic HBV infection and its associated complications in Singapore was US$279 million (range US$34-941 million when allowing various assumptions as tested by the sensitivity analyses), with 58% or US$161 million attributable to direct cost. Based on the base-case estimation, total direct cost alone is equivalent to 12% of the national healthcare expenditure for 2003. The total cost incurred by chronic hepatitis B patients represents the biggest cost component, followed by decompensated cirrhosis (DC) patients. The ratio of direct to indirect costs based on the base-case estimation increased with disease severity, with the highest ratio obtained for the post-liver transplants (40.2:1), followed by hepatocellular carcinoma (7.4:1) and DC patients (2.7:1). The results of this study suggest that the management of HBV infection poses more than a medical challenge as it is a sizeable economic burden from both the payer and societal perspectives.
S C Ong; S G Lim; S C Li
Related Documents :
18058038 - Hepatitis b viral factors and clinical outcomes of chronic hepatitis b.
16844238 - Hepatitis b virus is inhibited by rna interference in cell culture and in mice.
4088008 - Double infections with hepatitis a and b viruses.
18795708 - Living donor liver transplantation for hepatitis b associated liver diseases: a 10-year...
22617838 - Role of novel type i interferon epsilon in viral infection and mucosal immunity.
18442788 - Effect of oral immunomodulator dzherelo in tb/hiv co-infected patients receiving anti-t...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of viral hepatitis     Volume:  16     ISSN:  1365-2893     ISO Abbreviation:  J. Viral Hepat.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-02-04     Completed Date:  2009-02-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435672     Medline TA:  J Viral Hepat     Country:  England    
Other Details:
Languages:  eng     Pagination:  53-63     Citation Subset:  IM    
Department of Pharmacy, National University of Singapore, Singapore.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Cost of Illness
Health Care Costs*
Hepatitis B / economics*,  epidemiology*
Middle Aged
Singapore / epidemiology

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Validation of a commercially available immunoassay for the measurement of bovine cardiac troponin I.
Next Document:  Genotype D amongst injection drug users with acute hepatitis B virus infection in British Columbia.